Chapter 23 of 25
- Keep treatment summary
- Attend individualized visits
- Report new persistent symptoms between visits
- Treat late effects and support daily life
What you will learn
Understand the purpose of visits and tests; recognize symptoms between visits; build a survivorship plan.
What happens at follow-up
Visits review symptoms, medicines, emotional wellbeing and physical recovery. Examination commonly includes a pelvic assessment when appropriate. The schedule depends on treatment, recurrence risk, local guidance and individual needs; visits are often closer together in the first years and become less frequent over time. Ask for a written schedule and a route for earlier review.
After chemoradiation, response imaging is usually timed to allow treatment-related inflammation to settle; European guidance advises assessment imaging no earlier than about three months after completion. An uncertain finding may require repeat assessment or biopsy. Imaging immediately after treatment can be misleading, so timing should be explained rather than interpreted as neglect.
Tests should answer a question
Routine CT, PET-CT, blood tests or tumour markers are not automatically required at every visit. Imaging is guided by symptoms, examination, risk and the particular follow-up protocol. Cytology after radiation has limitations and is not a reliable substitute for clinical assessment of recurrence. Follow-up after fertility-sparing treatment or high-grade precancer has different requirements from follow-up after definitive cancer treatment.
A normal scan is reassuring for what it can detect at that time, not a lifetime guarantee. Equally, a scan abnormality may reflect inflammation, scarring or an unrelated condition. Ask what finding is being investigated and what the next decision would be for each possible result.
Symptoms to report between visits
Do not wait for the next scheduled appointment if there is new or persistent vaginal bleeding, pelvic or back pain, unexplained weight loss, leg swelling, urinary or bowel changes, cough or breathlessness. These symptoms have many possible causes, including treatable late effects. Reporting them enables assessment; it does not mean assuming recurrence.
If recurrence is confirmed, ask whether it is local, regional or distant and whether a local salvage option exists. Previous radiation details and treatment records are especially important. Supportive and palliative care can accompany further anticancer treatment and help manage uncertainty and symptoms.
Long-term health and recovery
Review vaginal dryness or narrowing, sexual pain, menopause symptoms, bladder and bowel changes, lymphoedema, neuropathy and bone health. Pelvic radiation can contribute to insufficiency fractures; persistent new pelvic pain merits evaluation. Hormone treatment, pelvic rehabilitation and specialist referral may be appropriate depending on individual risk.
Return to work, caring roles and physical activity may need a staged plan. Some people feel emotionally worse after treatment ends because appointments become less frequent and family expect a quick return to normal. Fear of recurrence is common; counselling and clear symptom guidance can help. Continue general preventive care, tobacco cessation and recommended screening for other conditions.
Your survivorship record
Keep the diagnosis and stage, pathology, operation details, radiation fields and dates, systemic medicines, significant toxicities and follow-up contacts. Include fertility or menopause advice and any ongoing monitoring, such as thyroid checks after immunotherapy. Share this summary with primary care and new clinicians.
Misconception and common question
“More scans always mean better follow-up” is false. Does reaching five years mean recurrence is impossible? No, although risks change over time; symptoms and late effects still deserve attention.
Take-home messages
Know the follow-up schedule and urgent contact route. Report new persistent symptoms. Recovery includes sexual, emotional and functional health, not only scan results.
References and review status
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
- NCI — Follow-up medical care after cancer treatment
- NCI — Support for people with cancer and families
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy